Tarín Juan J, García-Pérez Miguel A, Hermenegildo Carlos, Cano Antonio
Department of Functional Biology and Physical Anthropology, Faculty of Biological Sciences, University of Valencia, Burjassot, Valencia 46100, Spain.
Reprod Biol Endocrinol. 2014 Jun 23;12:56. doi: 10.1186/1477-7827-12-56.
In Western gender-neutral countries, the sex ratio at birth is estimated to be approximately 1.06. This ratio is lower than the estimated sex ratio at fertilization which ranges from 1.07 to 1.70 depending on the figures of sex ratio at birth and differential embryo/fetal mortality rates taken into account to perform these estimations. Likewise, little is known about the sex ratio at implantation in natural and assisted-reproduction-treatment (ART) cycles. In this bioessay, we aim to estimate the sex ratio at fertilization and implantation using data from embryos generated by standard in-vitro fertilization (IVF) or intracytoplasmic sperm injection (ICSI) in preimplantation genetic diagnosis cycles. Thereafter, we compare sex ratios at implantation and birth in cleavage- and blastocyst-stage-transfer cycles to propose molecular mechanisms accounting for differences in post-implantation male and female mortality and thereby variations in sex ratios at birth in ART cycles.
A literature review based on publications up to December 2013 identified by PubMed database searches.
Sex ratio at both fertilization and implantation is estimated to be between 1.29 and 1.50 in IVF cycles and 1.07 in ICSI cycles. Compared with the estimated sex ratio at implantation, sex ratio at birth is lower in IVF cycles (1.03 after cleavage-stage transfer and 1.25 after blastocyst-stage transfer) but similar and close to unity in ICSI cycles (0.95 after cleavage-stage transfer and 1.04 after blastocyst-stage transfer).
In-vitro-culture-induced precocious X-chromosome inactivation together with ICSI-induced decrease in number of trophectoderm cells in female blastocysts may account for preferential female mortality at early post-implantation stages and thereby variations in sex ratios at birth in ART cycles.
在西方性别中立的国家,出生时的性别比估计约为1.06。这个比例低于受精时估计的性别比,受精时的性别比根据出生时的性别比数据以及用于进行这些估计时所考虑的不同胚胎/胎儿死亡率,范围在1.07至1.70之间。同样,关于自然受孕和辅助生殖治疗(ART)周期中着床时的性别比,人们了解甚少。在本生物论文中,我们旨在利用植入前基因诊断周期中通过标准体外受精(IVF)或卵胞浆内单精子注射(ICSI)产生的胚胎数据,来估计受精和着床时的性别比。此后,我们比较卵裂期和囊胚期移植周期中着床时和出生时的性别比,以提出分子机制来解释植入后男性和女性死亡率的差异,从而解释ART周期中出生时性别比的变化。
基于PubMed数据库搜索确定的截至2013年12月的出版物进行文献综述。
IVF周期中受精和着床时的性别比估计在1.29至1.50之间,而ICSI周期中为1.07。与估计的着床时性别比相比,IVF周期中出生时的性别比更低(卵裂期移植后为1.03,囊胚期移植后为1.25),但ICSI周期中相似且接近1(卵裂期移植后为0.95,囊胚期移植后为1.04)。
体外培养诱导的早熟X染色体失活,以及ICSI诱导的女性囊胚中外胚层细胞数量减少,可能是导致植入后早期女性优先死亡的原因,从而导致ART周期中出生时性别比的变化。